PULMONARY EMBOLISM and Potassium

PatientsVille

Find and Compare Side Effects

PULMONARY EMBOLISM Symptoms and Causes

A pulmonaryembolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Pulmonaryembolism is a serious condition that can cause

Permanent damage to the affected lung

Low oxygen levels in your blood

Damage to other organs in your body from not getting enough oxygen

If a clot is large, or if there are many clots, pulmonaryembolism can cause death.

Half the people who have pulmonaryembolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. The goal of treatment is to break up clots and help keep other clots from forming.

PULMONARY EMBOLISM Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Impact on serum Potassium monitoring during Potassium-increasing drug-drug-interactions; Frequency of hyperkalemia during Potassium-increasing drug-drug-interactions; Frequency of Potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia; Frequency of transfers to the ICU during Potassium-increasing drug-drug-interactions in function of the serum Potassium level; Frequency of death during Potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia; Change in frequency distribution of serum Potassium monitoring intervals; Response of physicians to the computer-based alerts and reminders

The efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum Potassium levels in milliequivalent/liter (mEq/L) after Potassium replacement; Comparison of adverse effects after EPR and IVPR.; Comparison of number of dose/s required to achieve resolution of hypokalemia; Efficacy of EPR and IVPR for various degrees of severity of hypokalemia for each episode of hypokalemia

Blood pressure and markers of target organ damage and bone health at 4 weeks of Potassium supplementation.; Comparisons among different treatments in blood pressure and markers of target organ damage and bone health.

The primary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary N-telopeptide/creatinine ratio; The secondary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary nitrogen/creatinine ratio

changes of 24 hours proteinuria after the treatment; changes of serum creatinine after treatment; changes of eGFR after the treatment; changes of Traditional Chinese Medicine syndrome scores after the treatment

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.